利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.027 秒)

    Disialofucoganglioside immunogen and fucoganglioside monosialosyl Le.sup.a II
    4.
    发明授权
    Disialofucoganglioside immunogen and fucoganglioside monosialosyl Le.sup.a II 失效
    唾液中神经节苷脂免疫原和神经节苷脂单唾液酸Lea II

    公开(公告)号：US5011920A

    公开(公告)日：1991-04-30

    申请号：US348688

    申请日：1989-05-05

    申请人： Sen-itiroh Hakomori ,  Yasuo Fukushi ,  Edward D. Nudelman ,  Steven B. Levery

    发明人： Sen-itiroh Hakomori ,  Yasuo Fukushi ,  Edward D. Nudelman ,  Steven B. Levery

    IPC分类号： C07H15/10 ,  C07K16/30

    CPC分类号： C07H15/10 ,  C07K16/3046 ,  Y10S530/861

    摘要： Disialosyl Le.sup.a (IV.sup.3 NeuAcIII.sup.6 NeuAcIII.sup.4 FucLc.sub.4), a novel human cancer-associated fucoganglioside that is highly immunogenic. Also, a hybridoma cell line (ATCC No. HB 8861) secreting a monoclonal IgG3 antibody (FH7) directed to disialosyl Le.sup.a. The disialosyl Le.sup.a antigen was detected in various cancer tissues and their cell lines but was absent in various normal tissues and blood cells. Sera of patients with various cancers, particularly early cases of colonic and gastric cancers, showed an elevated disialosyl Le.sup.a antigen level, which subsequently decreased after surgical tumor removal.

    摘要翻译： 二唾液酸Lea（IV3NeuAcIII6NeuAcIII4FucLc4）是一种高度免疫原性的新型人类癌症相关的神经节苷脂。 此外，分泌针对二唾液酸Lea的单克隆IgG3抗体（FH7）的杂交瘤细胞系（ATCC No.BB8861）。 在各种癌组织及其细胞系中检测到二唾液酸Lea抗原，但在各种正常组织和血细胞中不存在。 各种癌症患者的血清，特别是结肠和胃癌的早期病例，显示出升高的二唾液酸Lea抗原水平，其随后手术切除肿瘤后降低。

    Naturally occurring gangliosides containing de-N-acetyl-sialic acid and their applications as modifiers of cell physiology
    5.
    发明授权
    Naturally occurring gangliosides containing de-N-acetyl-sialic acid and their applications as modifiers of cell physiology 失效
    含有脱-N-乙酰唾液酸的天然存在的神经节苷脂及其作为细胞生理学改性剂的应用

    公开(公告)号：US5272138A

    公开(公告)日：1993-12-21

    申请号：US467458

    申请日：1990-01-19

    申请人： Sen-itiroh Hakomori ,  Gustavo A. Nores ,  Nobuo Hanai ,  Taeko Dohi ,  Steven B. Levery ,  Mary Ellen K. Salyan ,  Hisao Nojiri

    发明人： Sen-itiroh Hakomori ,  Gustavo A. Nores ,  Nobuo Hanai ,  Taeko Dohi ,  Steven B. Levery ,  Mary Ellen K. Salyan ,  Hisao Nojiri

    IPC分类号： A61K31/70 ,  C07H15/10 ,  A61K31/725 ,  C07H5/06 ,  C07H13/06

    CPC分类号： C07H15/10 ,  A61K31/70

    摘要： A method for preparing de-N-acylated forms of an N-acyl sugar-containing glycosphingolipid and lyso forms of glycosphingolipid comprising hydrolyzing the glycosphingolipids under mild alkaline conditions such that the N-acyl group of the sugar moiety is preferentially hydrolyzed. Substantially pure gangliosides containing de-N-acetyl-sialic acid isolated from natural sources. A culture medium for stimulating growth of human and animal cells comprising: essential nutrients for cell growth, and a cell growth stimulatory amount of one or more gangliosides containing de-N-acetyl-sialic acid. A method for stimulating growth of human and animal cells cultured in vitro with a cell growth stimulatory amount of one or more gangliosides containing de-N-acetyl-sialic acid. A medicament and method for stimulating or inhibiting growth of human and animal cells by stimulating or inhibiting the production of growth stimulators selected from the group consisting of gangliosides containing de-N-acetyl-sialic acid, substances that promote synthesis of gangliosides containing de-N-acetyl-sialic acid and pharmaceutically acceptable salts thereof.

    摘要翻译： 一种制备N-酰基糖型鞘糖脂的N-脱酰基形式的方法，其包括在温和碱性条件下水解糖鞘脂，使糖部分的N-酰基优先水解。 含有从天然来源分离的脱-N-乙酰唾液酸的纯粹神经节苷脂。 用于刺激人和动物细胞生长的培养基包括：用于细胞生长的必需营养物和含有脱-N-乙酰唾液酸的一种或多种神经节苷脂的细胞生长刺激量。 用于刺激体外培养的细胞生长刺激量的含有脱-N-乙酰唾液酸的一种或多种神经节苷脂的人和动物细胞生长的方法。 通过刺激或抑制选自包含脱-N-乙酰唾液酸的神经节苷脂的生长刺激剂的生成来刺激或抑制人和动物细胞生长的药物和方法，促进含有脱-N-乙酰唾液酸的神经节苷脂合成的物质 乙酰唾液酸及其药学上可接受的盐。

    Monoclonal antibody that specifically binds to disialosyl Le.sup.a
    6.
    发明授权
    Monoclonal antibody that specifically binds to disialosyl Le.sup.a 失效
    特异性结合二唾液酸Lea的单克隆抗体

    公开(公告)号：US4851511A

    公开(公告)日：1989-07-25

    申请号：US824172

    申请日：1986-01-30

    申请人： Sen-itiroh Hakomori ,  Yasuo Fukushi ,  Edward D. Nudelman ,  Steven B. Levery

    发明人： Sen-itiroh Hakomori ,  Yasuo Fukushi ,  Edward D. Nudelman ,  Steven B. Levery

    IPC分类号： C07H15/10 ,  C07K16/30

    CPC分类号： C07H15/10 ,  C07K16/3046 ,  Y10S424/804 ,  Y10S530/861

    摘要： Disialosyl Le.sup.a (IV.sup.3 NeuAcIII.sup.6 NeuAcIII.sup.4 FucLc.sub.4), a novel human cancer-associated fucoganglioside that is highly immunogenic. Also, a hybridoma cell line (ATCC No. HB 8861)secreting a monoclonal IgG3 antibody (FH7) directed to disialosyl Le.sup.a. The disialosyl Le.sup.a antigen was detected in various cancer tissues and their cell lines but was absent in various normal tissues and blood cells. Sera of patients with various cancers, particularly early cases of colonic and gastric cancers, showed an elevated disialosyl Le.sup.a antigen level, which subsequently decreased after surgical tumor removal.

    摘要翻译： 二唾液酸Lea（IV3NeuAcIII6NeuAcIII4FucLc4）是一种高度免疫原性的新型人类癌症相关的神经节苷脂。 此外，分泌针对二唾液酸Lea的单克隆IgG3抗体（FH7）的杂交瘤细胞系（ATCC No.BB8861）。 在各种癌组织及其细胞系中检测到二唾液酸Lea抗原，但在各种正常组织和血细胞中不存在。 各种癌症患者的血清，特别是结肠和胃癌的早期病例，显示出升高的二唾液酸Lea抗原水平，其随后手术切除肿瘤后降低。

    Extended type 1 chain glycosphingolipids as tumor-associated antigens
    9.
    发明授权
    Extended type 1 chain glycosphingolipids as tumor-associated antigens 有权
    扩展型1型链鞘糖脂作为肿瘤相关抗原

    公开(公告)号：US06294523B1

    公开(公告)日：2001-09-25

    申请号：US09272755

    申请日：1999-03-22

    申请人： Steven B. Levery ,  Sen-itiroh Hakomori ,  Mark R Stroud

    发明人： Steven B. Levery ,  Sen-itiroh Hakomori ,  Mark R Stroud

    IPC分类号： A61K31715

    CPC分类号： A61K31/715 ,  C07K2317/732 ,  C07K2317/734 ,  C08B37/006

    摘要： A variety of compounds are provided which are useful as immunogens and as tumor markers. The present invention discloses methods relating to the detection of cancer. Extended forms of the lacto-series type 1 chain are shown to be present in various cancer tissues. The present invention also provides a cell line and the monoclonal antibody produced therefrom. Such an antibody has a number of uses, including in diagnostic or therapeutic methods.

    摘要翻译： 提供了可用作免疫原和肿瘤标记物的各种化合物。 本发明公开了与癌症的检测有关的方法。 乳糖系列1型链的延伸形式显示存在于各种癌组织中。 本发明还提供了由其制备的细胞系和单克隆抗体。 这样的抗体具有许多用途，包括诊断或治疗方法。

    Methods for glyco-engineering plant cells for controlled human O-glycosylation
    10.
    发明授权
    Methods for glyco-engineering plant cells for controlled human O-glycosylation 有权
    糖酵解植物细胞用于受控人O-糖基化的方法

    公开(公告)号：US09024110B2

    公开(公告)日：2015-05-05

    申请号：US13070248

    申请日：2011-03-23

    申请人： Zhang Yang ,  Damian Paul Drew ,  Emma Adhiambo Arigi ,  Peter Ulvskov ,  Steven B. Levery ,  Eric Bennett ,  Henrik Clausen ,  Brent Larsen Petersen

    发明人： Zhang Yang ,  Damian Paul Drew ,  Emma Adhiambo Arigi ,  Peter Ulvskov ,  Steven B. Levery ,  Eric Bennett ,  Henrik Clausen ,  Brent Larsen Petersen

    IPC分类号： C12N15/82 ,  C12N15/12 ,  C12N15/30 ,  C12N15/31 ,  C12N9/10 ,  C12N9/90 ,  C12P19/00 ,  C12P19/44 ,  A61K38/47 ,  C12N1/13 ,  C07K14/47 ,  C12P21/00

    CPC分类号： C12N15/8257 ,  C07K14/4727 ,  C12N15/8245 ,  C12P21/005

    摘要： This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon α2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation. Introduction of O-glycosylation into plant cells requires i) that wild-type plant cells do not modify the target peptide substrates and ii) that the appropriate enzymes and substrates are introduced into of plant cells such that O-glycosylation in the secretory pathway proceed and the glycosylated peptide substrates are preferentially exported to the exterior of the cell or accumulated in the cell. In this invention i) the integrity of transiently and stably expressed ‘mucin’ type target peptides in plants cells has been determined and ii) mucin-type O-glycosylation has been established in plants by transient and stable introduction of a Pseudomonas aeruginosa C4-epimerase, the human polypeptide GalNAc-transferases T2 and T4 (GalNAc-T2 and T4) and various human target peptides or proteins. In the present invention GalNAc-T2 and -T4 have been used to produce a Tn cancer glycoform of MUC1.

    摘要翻译： 本发明公开了在植物中重组生物活性糖蛋白和癌特异性疫苗重组生产的新平台的开发。 植物和植物细胞培养物相对于人粘蛋白型蛋白O-糖基化已被人源化。 已经开发了一组用于生产具有设计的人O-糖基化的重组糖蛋白的植物细胞工厂，包括改进的癌症疫苗候选物。 该平台为i）生产基本上无限量的O-糖基化的人类糖蛋白治疗剂例如人干扰素α2B和podoplanin的基础，以及ii）用于在治疗价值的糖蛋白上进一步工程化另外的癌症特异性O-聚糖。 目前，哺乳动物细胞是人O-糖基化所必需的，但由于它们不进行人类O-糖基化，植物提供了独特的用于工程化O-糖基化的细胞平台。 将O-糖基化引入到植物细胞中需要i）野生型植物细胞不修饰靶肽底物，和ii）将合适的酶和底物引入植物细胞，使分泌途径中的O-糖基化进行， 糖基化肽底物优选地输出到细胞的外部或者积聚在细胞中。 在本发明中，i）已经确定了植物细胞中瞬时稳定表达的“粘蛋白”型靶肽的完整性，并且ii）通过暂时稳定地引入铜绿假单胞菌C4差向异构酶，在植物中建立了粘蛋白型O-糖基化 ，人多肽GalNAc-转移酶T2和T4（GalNAc-T2和T4）和各种人靶肽或蛋白质。 在本发明中，已经使用GalNAc-T2和-T4来产生MUC1的Tn癌糖蛋白。